SciSparc announced its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment. The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRC:
- SciSparc delivers treatment for ASD trial enabling commencement of dosing
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
- SciSparc files to sell 5.4M ordinary shares for holders
- Clearmind Medicine submits three additional international patent applications
- SciSparc says Clearmind files three new international patent applications